{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:12Z","timestamp":1792783332597,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"OiSS","award":["JPMJOP1721"],"award-info":[{"award-number":["JPMJOP1721"]}]},{"name":"AMED","award":["22ck0106577h000, JP23ym0126091"],"award-info":[{"award-number":["22ck0106577h000, JP23ym0126091"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The performance of\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled prostate-specific membrane antigen (\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007) positron emission tomography\/computed tomography (PET\/CT) and bone scintigraphy (BS) for detecting bone metastases in prostate cancer patients was compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      One hundred prostate cancer patients (initial staging,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; biochemical recurrence,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200963; metastatic castration-resistant prostate cancer (mCRPC),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915; m0CRPC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT and BS. The patient-, region-, and lesion-based performances of\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT and BS for detecting bone metastases were evaluated by experienced readers using a five-point scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bone metastases were identified in 46 (46.0%) patients, 99 (24.8%) of the 400 regions, and 528 lesions. In the analysis, the area under the receiver-operating-characteristic curve (AUC), sensitivity, specificity, and accuracy values for\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT were 0.9985, 100%, 94.4%, and 97.0%, respectively, whereas those for BS were 0.8507, 71.7%, 88.9%, and 81.0%, respectively. AUC, sensitivity, and accuracy were significantly higher for\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT than for BS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00021,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00087, and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00018, respectively; McNemar test).\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT detected 527 of the 528 metastatic lesions (99.8%), whereas BS detected 253 (47.9%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The numbers of patients with (a) no bone metastases, (b) oligometastatic disease (1\u20133 lesions), (c) 4\u20135 lesions, (d) 6\u201320 lesions, and (e)\u2009&gt;\u200920 lesions for BS were 13, 21, 0, 8, and 4, respectively, compared with 0, 27, 3, 9, and 7, respectively, on\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT. In addition,\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT detected local recurrence (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951), nodal metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200937), and visceral metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT demonstrated higher sensitivity and accuracy than BS for detecting bone metastases in prostate cancer patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-02081-8","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:58:22Z","timestamp":1791003502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic accuracy of 18F-PSMA-1007 PET\/CT and bone scintigraphy for detecting bone metastases in prostate cancer"],"prefix":"10.1007","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahiro","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-2395","authenticated-orcid":false,"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2081_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329. https:\/\/doi.org\/10.3322\/caac.21254.","journal-title":"CA Cancer J Clin"},{"key":"2081_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165\u201376. https:\/\/doi.org\/10.1053\/ctrv.2000.0210.","journal-title":"Cancer Treat Rev"},{"key":"2081_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2010.10.039.","journal-title":"Eur Urol"},{"issue":"12 Suppl","key":"2081_CR4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::aid-cncr14>3.3.co;2-h","volume":"88","author":"BI Carlin","year":"2000","unstructured":"Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989\u201394. https:\/\/doi.org\/10.1002\/1097-0142(20000615)88:12+%3C2989::aid-cncr14%3E3.3.co;2-h.","journal-title":"Cancer"},{"key":"2081_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.beem.2008.01.011","volume":"22","author":"P Msaouel","year":"2008","unstructured":"Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab. 2008;22:341\u201355. https:\/\/doi.org\/10.1016\/j.beem.2008.01.011.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6 Pt 1","key":"2081_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","volume":"171","author":"S Abuzallouf","year":"2004","unstructured":"Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1):2122\u20137. https:\/\/doi.org\/10.1097\/01.ju.0000123981.03084.06.","journal-title":"J Urol"},{"key":"2081_CR7","first-page":"53","volume":"45","author":"LD Rybak","year":"2001","unstructured":"Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53\u201364.","journal-title":"Q J Nucl Med"},{"key":"2081_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0022-5347(01)62545-X","volume":"160","author":"ML Cher","year":"1998","unstructured":"Cher ML, Bianco FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387\u201391.","journal-title":"J Urol"},{"key":"2081_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00259-013-2532-6","volume":"41","author":"H Palmedo","year":"2014","unstructured":"Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, T\u00fcrler A, et al. Whole-body SPECT\/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59\u201367. https:\/\/doi.org\/10.1007\/s00259-013-2532-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2081_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13:226\u201335. https:\/\/doi.org\/10.1038\/nrurol.2016.26.","journal-title":"Nat Rev Urol"},{"key":"2081_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2081_CR12","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114\u201321. https:\/\/doi.org\/10.1007\/s00259-016-3435-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2081_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clgc.2018.07.009","volume":"16","author":"T Lengana","year":"2018","unstructured":"Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET\/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? Clin Genitourin Cancer. 2018;16:392\u2013401. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.009.","journal-title":"Clin Genitourin Cancer"},{"key":"2081_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3906\/sag-1807-4","volume":"49","author":"L Uslu-Be\u015fli","year":"2019","unstructured":"Uslu-Be\u015fli L, Sa\u011fer S, Akg\u00fcn E, Asa S, \u015eahin OE, Demirda\u011f \u00c7, et al. Comparison of Ga-68 PSMA positron emission tomography\/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients. Turk J Med Sci. 2019;49:301\u201310. https:\/\/doi.org\/10.3906\/sag-1807-4.","journal-title":"Turk J Med Sci"},{"key":"2081_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-020-00618-0","volume":"10","author":"HD Zacho","year":"2020","unstructured":"Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res. 2020;10:31. https:\/\/doi.org\/10.1186\/s13550-020-00618-0.","journal-title":"EJNMMI Res"},{"key":"2081_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12149-020-01529-9","volume":"34","author":"M Caglar","year":"2020","unstructured":"Caglar M, Tuncel M, Yildiz E, Karabulut E. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET\/CT. Ann Nucl Med. 2020;34:932\u201341. https:\/\/doi.org\/10.1007\/s12149-020-01529-9.","journal-title":"Ann Nucl Med"},{"key":"2081_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12149-020-01474-7","volume":"34","author":"DH Simsek","year":"2020","unstructured":"Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, et al. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET\/CT in prostate cancer? Ann Nucl Med. 2020;34:476\u201385. https:\/\/doi.org\/10.1007\/s12149-020-01474-7.","journal-title":"Ann Nucl Med"},{"key":"2081_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00259-020-04867-y","volume":"48","author":"IO Lawal","year":"2021","unstructured":"Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, et al. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET\/CT, [68Ga]Ga-NODAGAZOLPET\/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. Eur J Nucl Med Mol Imaging. 2021;48:134\u201342. https:\/\/doi.org\/10.1007\/s00259-020-04867-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 3","key":"2081_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bju.16115","volume":"133","author":"R Shanmugasundaram","year":"2024","unstructured":"Shanmugasundaram R, Saad J, Heyworth A, Wong V, Pelecanos A, Arianayagam M, et al. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography\/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis. BJU Int. 2024;133(Suppl 3):25\u201332. https:\/\/doi.org\/10.1111\/bju.16115.","journal-title":"BJU Int"},{"key":"2081_CR20","first-page":"395","volume":"11","author":"L Saule","year":"2021","unstructured":"Saule L, Radzina M, Liepa M, Roznere L, Kalnina M, Lioznovs A, et al. Diagnostic scope of 18F-PSMA-1007 PET\/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am J Nucl Med Mol Imaging. 2021;11:395\u2013405.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2081_CR21","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1007\/s00259-026-07931-1","volume":"53","author":"Y Liu","year":"2026","unstructured":"Liu Y, Hatano K, Uemura M, Hirata T, Naka S, Kurimoto K, et al. Diagnostic impact of interpretation criteria for [18F]PSMA-1007 PET\/CT: Prospective comparison with CT and bone scan. Eur J Nucl Med Mol Imaging. 2026;53:5782\u201394. https:\/\/doi.org\/10.1007\/s00259-026-07931-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2081_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.008","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Eur Urol. 2023;84:491\u2013502. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.008. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0."},{"key":"2081_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"2081_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41181-020-00101-0","volume":"5","author":"S Naka","year":"2020","unstructured":"Naka S, Watabe T, Kurimoto K, Uemura M, Soeda F, Neels OC, et al. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharm Chem. 2020;5:18. https:\/\/doi.org\/10.1186\/s41181-020-00101-0.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2081_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","volume":"68","author":"BA Gartrell","year":"2015","unstructured":"Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68:850\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.039.","journal-title":"Eur Urol"},{"key":"2081_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1748-717X-9-135","volume":"9","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135. https:\/\/doi.org\/10.1186\/1748-717X-9-135.","journal-title":"Radiat Oncol"},{"key":"2081_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.bjc.6600715","volume":"88","author":"M Noguchi","year":"2003","unstructured":"Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88:195\u2013201. https:\/\/doi.org\/10.1038\/sj.bjc.6600715.","journal-title":"Br J Cancer"},{"issue":"10162","key":"2081_CR28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"key":"2081_CR29","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R, et al. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51:3753\u201364. https:\/\/doi.org\/10.1007\/s00259-024-06797-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2081_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00259-009-1334-3","volume":"37","author":"V Helyar","year":"2010","unstructured":"Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, et al. The added value of multislice SPECT\/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37:706\u201313. https:\/\/doi.org\/10.1007\/s00259-009-1334-3.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02081-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:58:24Z","timestamp":1791003504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02081-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":30,"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02081-8","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.eururo.2023.06.008","asserted-by":"subject"}]},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FLG is an advisor at ABX, Telix, SOFIE Biosciences, and \u03b1-Fusion and holds shares in the consultancy group iTheranostic.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}